Pay in 4 interest-free payments of $6.98 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: the CHAMP-HF registry
-Six months of needle therapy, Roche/Alnylam's new SiRNA antihypertensive drug is planned to be included in breakthrough therapies On June 2, 2026, the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Roche's Zilebesiran is intended to be included as a breakthrough therapy for adult hypertensive patients with cardiovascular disease or high risk of cardiovascular disease, in order to reduce the risk of cardiovascular death, non fatal myocardial infarction, non fatal stroke, and heart failure events (hospitalization or emergency treatment for heart failure)
Whether you are interested in the convenience of a daily pill or the high-efficacy results of traditional GLP-1 weight loss injections, MTCs comprehensive approach ensures your treatment matches your lifestyle and metabolic needs
Temporary Constipation Relief The fluid in the colon helps soften stool and stimulate peristalsis, providing short-term relief from constipation when needed
How Patient Demand Is Shaping Innovation The advancement of oral GLP-1 options reflects a significant response to patient preferences and demand
